Role of the Neuroinflammation in the Degree of Spinal Cord Injury: New Therapeutic Strategies by Paterniti, Irene et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 4
Role of the Neuroinflammation in the Degree of Spinal
Cord Injury: New Therapeutic Strategies
Irene Paterniti, Emanuela Esposito and
Salvatore Cuzzocrea
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/63222
Abstract
A case of spinal cord injury (SCI) is defined as the occurrence of an acute traumatic
lesion of neural elements in the spinal canal (spinal cord and cauda equina), resulting
in temporary or permanent sensory and/or motor deficit. Most studies on traumatic SCI
show a bimodal age distribution, with a first peak in young adulthood and a second
peak in older adults. Spinal cord trauma activates a cascade of events that exacerbates
the damage such as activation of inflammatory process that determinates cytokine and
chemokine production and that generates reduction in functional recovery resulting in
necrosis or apoptosis of neurons. However, the precise mechanism of SCI-induced
inflammatory response remains not fully understood at present. Current strategy to
treat damage to the spinal cord is limited, only the treatment with methylpredniso‐
lone (MP), if administered in excessive dose during the acute phase of the damage, could
ameliorate patients with severe SCI. However, associated to the beneficial effects, there
are growing evidence that high-dose of MP is correlated to increased risk of infec‐
tions,  pneumonia  and  gastrointestinal  bleeding.  Therefore,  there  is  a  necessity  to
develop new therapies to treat SCI; one of these is to selectively reduce inflammation
that possess unique role in the processes of injury and recovery.
Keywords: Immune response, oxidative stress, spinal cord injury, inflammation, neu‐
roprotection
1. Inflammation response after spinal cord injury
Spinal cord injury (SCI) is damage caused to the spinal cord that compromise the major functions
of the spinal cord and remains actually the most important cause of mortality in the society. In
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addition to its cost to the individual, physically as well as the health care system and society
financially, SCI has profound psychosocial effects that are devastating for patients, families and
friends. SCI usually begins with a sudden, traumatic blow to the spine that fractures or dislocates
vertebrae; long-term mechanical compression of the spinal cord gradually causes various
pathologic changes in neural tissue. The pathophysiology of SCI comprises both primary and
secondary mechanisms of injury; the “primary injury” refers to the forces that impart the primary
mechanical insult to the spinal cord, which in its mildest form causes a cord concussion with
brief transient neurologic deficits and in its most severe form causes complete and permanent
paralysis. The primary damage to tissue is followed by a second phase of tissue degeneration
that might occur over weeks or even months and further generate progressive destruction of
the tissue surrounding the necrotic core that expands from the injury “epicenter” and is known
as secondary injury, that is a persistence of some crucial events of the acute phase such as edema
and apoptotic cell death as well as generation of oxidative stress, activation of immune system
response and inflammation process. In particular we focus our attention on some mecha‐
nisms that occur after spinal cord injury such as on the involvement of the inflammation process
and immune system response.
Inflammation is a physiological process that removes damaged stimuli and initiates the healing
process; however, if it persists and if it is over-activated, then the inflammation becomes
devastating; inflammation is a key element in the pathophysiology of some disorders such as
chronic pain, neurodegenerative pathology, trauma and spinal cord injury [1–5]. Principal pro-
inflammatory markers that are both cellular components, such as neutrophils, macrophages
and T cells, and non-cellular components, such as cytokines, prostaglandins and complement,
have been found in spinal cord tissue that received a mechanical insult. Following spinal cord
trauma, the site of injury is penetrated by neutrophils, that determinate release of cytokines
that may progressive damage local tissue and recruit other inflammatory cells [6]; moreover,
monocytes/macrophages are released and locally activated in microglia, that subsequently
invade the injured tissue [7]. The pro-inflammatory cytokines that are produced at the site of
injury, such as tumor necrosis factor (TNF-α), interleukins and interferons, mediate the
inflammatory response and can generate further tissue damage [8,9]. Furthermore, cytokines
can induce the expression of cyclo-oxygenase (COX) 2 and thus promote the breakdown of
arachidonic acid into pro-inflammatory prostanoids (prostaglandins, prostacyclin and
thromboxanes) that mediate vascular permeability/resistance and platelet aggregation/
adherance [10,11]. The involvement of the cyclo-oxygenases in the generation of these
inflammatory mediators represents a potential target for intervention, because inhibitors of
these enzymes are in widespread clinical use. Additionally, TNF-α contributes to the tissue
injury induced by neutrophils by directly activating them [12,13] as well as by increasing the
expression of such molecules as ICAM-1 and E-selectin, which cause the activated neutrophils
to adhere to the surface of the endothelial cells; it has also been shown that the inhibition of
neutrophil adhesion to the endothelial cell surface markedly reduces the severity of the SCI
induced by compressive trauma [14]. These observations indicate that the interaction of
activated neutrophils with the surface of the endothelial cells is another important mediator
in the secondary tissue damage of the spinal cord.
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1.1. Cytokine responses to inflammation
Cytokines are small and non-structural proteins with no amino acid sequence motif, their
biological activities allow us in turn to group them into different classes: exit 18 cytokines called
interleukin (IL), some of these promote inflammation and are named pro-inflammatory
cytokines such as IL1β and IL1α, IL6, IL8 and TNF-α, whereas other cytokines suppress the
activity of pro-inflammatory cytokines and are called anti-inflammatory cytokines such as
IL-4, IL-10, TGFβ. The hypothesis that some cytokine functions primarily induce inflammation
while others suppress inflammation is essential to cytokine biology and also to clinical
medicine.
Cytokines are secreted by a variety of immune cells such as T-lymphocytes and macrophages,
as well as b non-immune cells such as fibroblasts; the physiological effects mediated by
cytokines comprise the stimulation or inhibition of cell growth, cytotoxicity/apoptosis,
antiviral activity and inflammatory responses. The main function of cytokines is the regulation
of T-cell differentiation from undifferentiated cells to T-helper 1 and 2, regulatory T cells, and
T-helper 17 cells [15]. These regulatory proteins include ILs, interferons (IFNs) and TNFs.
Many of these cytokines have already been shown to be produced by neurons or glia in central
nervous system (CNS) disorders in which they are notably increased.
The cytokine class of inflammatory mediators is secreted by microglia and astrocytes and their
production is increased in inflammatory states; moreover they act by modulating the intensity
and duration of the immune response. Pro-inflammatory cytokines and chemokines up-
regulate microbicidal activity of neutrophils, and they can be considered as additional
immunomodulatory agents to treat serious or refractory infections in humans.
Through cytokines IL-1 the immune response is initiated, having a crucial role in the onset and
expansion of a complex hormonal and cellular inflammatory cascade; the IL-1 family of
cytokines includes IL-1α and IL-1β, which generate cell activation upon binding with specific
membrane receptors and has been documented that IL-1 plays a role in neuronal degeneration.
In astrocytes, IL-1 induces IL-6 production, stimulates iNOS activity [16], enhances neuronal
acetylcholinesterase activity, microglial activation and additional IL-1 production, and
astrocyte activation.
Another important pro-inflammatory cytokine is the IL-6, a multifunctional cytokine that plays
an important role in host defence [17] and possesses main effects during the inflammatory
response [18]. IL-6 is associated to the family of neuropoietin cytokine and it possesses direct
and indirect neurotrophic effects on neurons [19]; moreover, IL-6 promotes astrogliosis [20],
activates microglia [21], and stimulates the release of acute phase molecules.
1.2. Inflammatory mediator: crucial role of TNF-α
Through all the cytokines involved in the secondary damage, TNF-α plays a crucial role; in
fact it releases shortly after injury, it can accumulate rapidly at the site of injury, and it is
produced by a number of different cell populations, such as neutrophils, macrophages and
microglia, astrocytes and T cells [22]. Several cell types are able to produce TNF-α, including
macrophages after its activation, dendritic cells, monocytes, NK cells, CD4+ T cells, CD8+ T
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cells, microglia and astrocytes. Macrophages/monocytes are able to produce TNF-α in the
acute phase of inflammation and this cytokines drives several range of signalling events within
cells, leading to necrosis or apoptosis.
Several biological functions are ascribed to the TNF-α and for this reason the mechanism of
action is somewhat complex; although it inhibits the growth of tumor cells and it has an
enhancing effect on the proliferation of normal cells [23]. TNF-α takes part in septic shock,
autoimmunity, and inflammatory disorders. The major role of TNF-α is explicated as mediator
in resistance against infections; moreover, it was postulated that TNF plays a pathological role
in a number of autoimmune pathology such as graft vs host rejection or rheumatoid arthritis.
Moreover, TNF-α possesses potent pro-inflammatory effects that are associated to its capacity
to generate endothelial cell adhesion molecules and subsequently support neutrophil adher‐
ence to vascular endothelium. Neutrophils are exquisite targets of TNF-α that is under certain
conditions it strengthens their expression of adhesion molecules induces their degranulation
and successive release of lysosomal enzymes, causing the production of highly reactive oxygen
species. TNF-α induces the migration of neutrophils mediating the production of chemotactic
factors, including IL-8; this testifies cytokine networking involvement in inflammatory cell
recruitment and an active role in inflammation.
TNF-α works by binding and clustering high-affinity receptors that are present in a great
numbers on most cell membranes [24], the ligand/receptor complex is easily internalised via
clathrin-coated pits and ends up in secondary lysozymes where it is degraded. Interestingly,
the binding of TNF-α to the 75 kDa TNFR-2 is not sufficient to reach cytotoxicity, but rather
binding to the 55 kDa TNFR-1 is sufficient to reach TNF-α mediated cell killing. TNF-α exerts
its effects by activating several secondary proteins that provoke a variety of responses within
the cell such as activation of gene transcription and/or production of reactive oxygen or
nitrogen radicals (e.g., NO). Activated proteins include Gprotein, transcription factors such as
NF-κB and AP-1 and serine and cysteine proteases, known as caspases. Many members of the
TNF receptor superfamily have intracellular “death domains” which represent protein
interaction domains each consisting of 65–80 amino acids; these proteins participate in TNF-
α mediated apoptosis process; many evidence demonstrated that TNF–TNFR interactions are
implicated in the pathogenesis of CNS disorders such as EAE and MS. These interactions are
able to monitor the disease outcome by modifying immune response and the interactions
between CNS-resident cells and effector immune cells in the CNS.
However, recent studies showed a dual nature for TNF-α that it can be not only neurotoxic
but also neuroprotective; a study conducted with transgenic mice for TNF-α receptors
demonstrated that the mice lacking TNF-α showed more tissue loss and functional deficits
compared to wild-type mice, implying that TNF-α mediated a neuroprotective effect [25]. The
beneficial or deleterious effects of TNF-α dependent when it is being released and on cellular
population that is acting on, the conflicting actions of TNF-α described above reflects a growing
view of inflammation as a “dual-edged sword” having neurotoxic and neuroprotective
properties [26].
Thus, comprehension of their profile, kinetics of expression and interactions between TNF-α
ligands and their TNFRs on different CNS residents and infiltrating immune cells would aid
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to better design strategies to control neuroinflammation and CNS autoimmunity. Blockers of
TNF-α have been acknowledged for human use in treating TNF-linked autoimmune and
inflammatory disorders. Pathways downstream of receptor ligation supply critical points for
interjection for planning new therapeutic strategies.
1.3. Microglia activation
Moreover, other important mediators of inflammation that respond rapidly to disturbances
within the microenvironment by change in morphology are the microglia, the expression
“activated microglia” is used to define cells that change their immunophenotype and their
morphology after a specific stimuli; the principal role of microglia at the lesion site is a rapid
phagocytosis of fragments and induction of apoptosis [27]. The different response of microglia
in vitro suggests that these cells may elicit unique functional properties and consequently
control the inflammatory response at the injury site. Microglial activation has been well-known
in the spinal cord tissue that has received a trauma and has shown to occur from caudal to
lumbar enlargement, based on that there are papers supporting the role of microglia in pain
after injury and showing activation of microglia post-SCI.
Thus, we postulated that activated spinal microglia have a role in chronic pain after SCI.
Microglia activate the innate immune system and are key regulators of inflammatory processes
in CNS pathologies such as trauma and neurodegenerative diseases participation in both acute
and chronic phase of the inflammatory responses. Activated microglia secrete cytotoxic
substances including various cytokines such as TNF-α, IL-1, reactive free radicals, and nitric
oxide. However, the principal effects of microglia at the levels of the lesion core are probably
rapid phagocytosis of debris rather than induction of apoptosis. Microglia when activated can
cause neuronal and glial toxicity through the release of cytokines, free radicals, eicosanoids,
activated neutrophils, and macrophages [28]. On the other hand, microglia activation leads to
beneficial effects producing growth factors that are fundamental for neuronal and tissue
restoration. Moreover, it has been demonstrated that transplantation of peripherally activated
macrophages has beneficial effects on spinal cord regeneration.
1.4. Apoptosis
In the last decade the generation of apoptotic process after spinal cord trauma was also
confirmed, apoptosis can be triggered by a variety of insults including cytokines, inflammatory
injury, free radical damage, and excitotoxicity.
The apoptotic process after spinal cord trauma is activated in neurons, oligodendrocytes,
microglia, and perhaps, astrocytes; apoptosis in microglia contributes to inflammatory
secondary injury.
Two main pathways of apoptosis—extrinsic or receptor-dependent and intrinsic or receptor-
independent—have been well characterized, and both appear to be active in SCI; the extrinsic
or receptor-dependent pathway is mediated by Fas ligand and Fas receptor [29] and/or
inducible nitric oxide synthase production by macrophages [30], while intrinsic or receptor-
Role of the Neuroinflammation in the Degree of Spinal Cord Injury: New Therapeutic Strategies
http://dx.doi.org/10.5772/63222
85
independent pathway is mediated via direct caspase-3 pro-enzyme activation [31] and/or
mitochondrial damage, release of cytochrome c and activation of the inducer caspase-9,
pathways of caspase-mediated apoptotic death [32].
Receptor-dependent apoptosis is evoked by extracellular signals, the most significant of which
is TNF, so it is termed as “extrinsic” pathway; TNF is known to rapidly accumulate in the
injured spinal cord, and activation of the Fas receptor of neurons, microglia, and oligoden‐
drocytes induces a programmed sequence of caspase activation. Moreover, additional control
of cell death/survival is provided by the balance between major pro-apoptotic proteins such
as Bax, Bad, and Bid and anti-apoptotic proteins such as Bcl-XL and Bcl-2.
Apoptotic cells were reached in the grey matter after injury, starting from 1h with a prolifer‐
ation during the other 8 h [33]. The number of apoptotic cells is increased at the site of injury
and are related with axons degeneration [34].
Apoptotic process that is activated in the secondary injury in SCI has recently come under
close study, and the precise contribution and potential therapeutic implications of apoptosis
in SCI could be helpful to generate new therapeutic approach to treat the secondary events
associated to spinal cord injury.
2. Inflammatory/immunologic response
The inflammatory and immunological response to injury within the CNS is different than that
which is occurring in other tissues [35]. The inflammatory and immunologic responses to
injury involve activation of innate immune cells that provide immediate defence against
inflammatory stimuli and in turn help to recruit cells of the adaptive immune system (i.e., T-
and B-lymphocytes). The activation of immune system is driven by interactions involving
presentation of antigen and release of various inflammatory mediators [36]. Also, cells present
at the injury site may sequester debris and carry CNS antigens to secondary lymphoid organs
[37], where trigger lymphocyte activation. Recent studies done on mice showed that the
number of activated T and B cells increases in the spleen and bone marrow within 24 hours of
trauma [38].
2.1. Lymphocytes infiltration
T-lymphocytes are distributed in the intact spinal cord and gradually grow in number after
trauma in parallel with the stimulation of microglia and influx of peripheral macrophages.
Lymphocytes infiltrate the spinal cord tissue starting from 24 hours until 7 days after injury
and return gradually back to normal levels in 4 to 5 weeks [14].
Under normal conditions, activated T cells can cross the Add Blood–brain barrier (BBB) and
enter the CNS parenchyma. In contrast with other inflammatory cells enrolled after a trauma,
the number of lymphocytes remains low [39]; however, T-lymphocytes play an important role
in the CNS immune system, since on activation, T-lymphocytes may kill target cells and
produce cytokines [40].
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Once lymphocytes enter the lesion site, they persist indeterminately [38,41], whereas T and B
cells increase at the lesion site at least 9 weeks post-injury [42,43], suggesting that cytokine/
chemokine gradients exist chronically and regulate integrin expression on endothelia and cells
[44,45]. These chemokine gradients and adhesion molecules represent molecular targets for
manipulating the effects of intraspinal lymphocytes after SCI [46–48]; the progressive increase
in lymphocyte numbers may also be justified by lymphocyte activation and proliferation
within the injured centre of spinal cord.
Moreover, induction of immune response could be generated as impaired nerve transmission;
increasing the production of pro-inflammatory cytokines in chronic phase of SCI could worsen
the damage increasing the axonal injury and demyelination. Furthermore, there are evidences
that autoreactive lymphocytes promote neuronal survival in vivo through activation not only
of autoreactive T cell but also through activation of other non-CNS reactive T cells or B cells
such as resident microglia and infiltrating macrophages.
Thus, because lymphocytes remain for long term at the site of the lesion; new strategy of
treatment could orientate on these cells that possess a fundamental role in regulating degen‐
erative and regenerative processes after injury.
3. Pharmacologic interventions for acute spinal cord injury
The temporal profile of the secondary injury cascade provides a window within which it is
theoretically possible to reduce the pathophysiological processes; many of the current
pharmacological and surgical strategies for the treatment of SCI are based on minimising
secondary injury and preserving neurological function following trauma to the brain and
spinal cord. Over the past couple of decades, a myriad of agents have been nominated as
putative neuroprotective therapies, several of these have been tested in the pre-clinical and
clinical studies.
The following section briefly highlights some of the most promising neuroprotective ap‐
proaches that are being pursued.
3.1. Corticosteroids
In the last decade one of the most used approaches to treat patients with a severe SCI is the
use of corticosteroids that possess a well-recognized anti-inflammatory properties reducing
spinal cord edema. However, the exact mechanisms by which corticosteroids mediated
neuroprotection are not yet completely understood but seems that they induce a reduction of
inflammatory cytokines production, modulation of the inflammatory/immune cells, inhibition
of lipid peroxidation and reduction of oxidative stress. In this regard, methylprednisolone
(MP) appears to be particularly efficacious compared with other glucocorticoids. According
to the National Acute Spinal Cord Injury Study 2 (NASCIS 2) protocol, MP is usually admin‐
istered within 8 h after trauma in a high concentration of 30 mg/kg, followed by an infusion
of 5.4 mg/kg/h for 23 hours [49,50]. MP is the only well-known pharmacological treatment of
SCI injury patients; however, its administration has been shown to be controversial. Some toxic
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effects such as infection rates, pulmonary embolism, severe pneumonia and sepsis and even
death secondary to respiratory complications appeared to be higher with steroid use.
The anti-inflammatory properties of MP are mediated by different mechanisms that are known
as transrepression, this mechanism involves interference with pro-inflammatory transcription
factor signalling (such as NF-κB) which is upstream of several inflammatory mediators
including COX2, chemokines and cytokines.
Together with the minor functional improvement in humans and risk of adverse side effects,
these studies highlighted the compelling need to develop better neuroprotective agents with
more convincing efficacy.
3.2. Estrogen as a neuroprotective agent
At present, several effects have been associated to estrogen that acts with different mechanism
of action [51]. Recently, the neuroprotective and anti-inflammatory effect of estrogen are of
great interest; leukocyte adhesion and microglia activation are also sensitive to estrogen and
show significantly decreased superoxide dismutase production and phagocytic activity when
treated with estrogen in vitro [52].
Moreover, cell death is associated to decreases blood flow in spinal cord and estrogen are
involved in increasing post-traumatic blood flow induced by ischemia [53] and TBI [54]. Thus,
estrogen treatment has been related with increased expression of pro-apoptotic Bcl-2 in the
spinal cord injured tissue, this anti-apoptotic increase in Bcl-2 may be mediated by Akt
activation with downstream phosphorylation of cAMP response element binding protein
(CREB) [55].
However, estrogen may also act on Add N-methyl-D-aspartate receptor (NMDA) receptors,
indicating a potential to limit secondary cell death due to excitotoxicity [56].
3.3. Nuclear hormone receptors family: PPARs receptor
Other members of the nuclear hormone receptors family (NHRs) are now explored for their
anti-inflammatory properties in experimental models, including SCI.
Peroxisome proliferator-activated receptors (PPARs) are part of the nuclear hormone receptor
superfamily, upon ligand activation regulate gene expression and have been shown to be anti-
inflammatory in different model of inflammatory pathology, including SCI. PPAR exists as
three isoforms (α, β/δ and γ) that control many cellular functions including lipid metabolism,
glucose absorption, cell growth and differentiation, and inflammation.
One mechanism involves direct interaction of PPAR with pro-inflammatory transcription
factors, most importantly NFκB and AP-1, and the subsequent reduction of gene transcription.
Pioglitazone and rosiglitazone are PPARγ agonists that are in common clinical use for type II
diabetes. Beyond their metabolic effects, interest in PPAR γ ligand has grown due to their anti-
inflammatory, neuroprotective, and even anti-neoplastic properties, suggesting its potential
use after spinal cord trauma [57]. As such, PPAR agonists have already been clinically tested
in other disorders with inflammatory pathology, such as Alzheimer’s disease (AD), rheuma‐
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toid arthritis (RA), and ischemia reperfusion injury, but not in SCI yet. Moreover, in the last
few years a great interest has been focused on other PPAR receptors agonist such as for
PPARα and β/δ receptors. One of the first reports indicating that PPARα is involved in
attenuating inflammation demonstrated that the eicosanoid LTB4 binds and activates PPARα
[58]. Several studies on inflammatory cytokine produced in aged mice demonstrated an active
interaction of PPARα with NFκB; in fact the oxidative stress in different tissue leads to active
NFκB. Treatment with PPARα agonists were found to restore the alteration of oxidative
mediators, to inhibit the activation of NFκB and to remove IL-6 and IL-12 produced [59,60].
These features were accompanied by enhanced functional motor recovery and reduced
hyperalgesia.
Since PPAR agonists are currently used in medical treatment of diabetes, clinical studies for
stroke and different CNS pathologies are to be expected. The knowledge about anti-inflam‐
matory properties of PPAR ligands obtained from cell cultures and animal model of SCI
demonstrate that PPARs signalling may be therapeutic targets after spinal cord injury.
4. Conclusion
Thus, recent researches are moving to develop new pharmacological approaches that may
offer an effective neuroprotection after spinal cord injury. After spinal cord injury, inflamma‐
tory reactions account for a large proportion of the secondary damage to neurons and
oligodendrocytes.
Promising research is being carried out to better understand the aspects of inflammation, lipid
peroxidation and apoptotic cell death that may be the target of pharmacologic intervention.
Few agents have been studied demonstrating efficacy in animal models of spinal cord injury
and may become appropriate for testing in the human setting in the near future.
Clearly, much effort has to be done to bring experimental strategies to clinical fruition, but
they do represent promising potential interventions.
Thus, the current medical and surgical interventions for the acutely cord-injured patient
attempt to minimize the inflammatory process that possess a crucial role in generating and
maintaining secondary damage associated to injury and defend the neural cells that initially
survived the mechanical injury.
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